Naftidrofuryl for intermittent claudication

Cochrane Database of Systematic Reviews

Volumn , Issue 2, 2008, Pages

  De Backer, Tine L M ^a   Vander Stichele, R ^b   Lehert, P ^b   Van Bortel, L ^b  

^a GHENT UNIVERSITY   (Belgium)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

NAFTIDROFURYL; PLACEBO;

ANGINA PECTORIS; AUTHOR; CALCULATION; CARDIOVASCULAR DISEASE; CLINICAL DECISION MAKING; CLINICAL EVALUATION; CLINICAL TRIAL; COCHRANE LIBRARY; COMPARATIVE STUDY; CONFIDENCE INTERVAL; DATA BASE; DATA EXTRACTION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; EMBASE; GEOMETRY; HEART INFARCTION; HUMAN; INFORMATION PROCESSING; INTERMITTENT CLAUDICATION; JOINT STIFFNESS; MEDLINE; META ANALYSIS; METHODOLOGY; NAUSEA; OUTCOME ASSESSMENT; PAIN; PATIENT CODING; PATIENT SELECTION; POSTMARKETING SURVEILLANCE; PUBLICATION; PUBLISHING; QUALITY CONTROL; REGISTER; REVIEW; RISK; RISK BENEFIT ANALYSIS; SCISEARCH; SENSITIVITY ANALYSIS; SIDE EFFECT; SKIN REDNESS; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; STOMACH PAIN; SYSTEMATIC REVIEW; URTICARIA; WALKING; WEIGHT REDUCTION; XEROSTOMIA;

EID: 44949203685     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD001368.pub3     Document Type: Review

References (56)

1. Adhoute 1986 {published and unpublished data} Adhoute G, Bacourt F, Barral M, Cardon JM, Chevalier JM, Cuny A, et al.Naftidrofuryl in chronic arterial disease. Results of a six month controlled multicenter study using naftidrofuryl tablets 200 mg. Angiology 1986;37:160-7.
2. Adhoute 1990 {published and unpublished data} Adhoute G, Andreassian B, Boccalon H, Cloarec M, Di Maria G, Lefebvre O, et al.Treatment of stage II chronic arterial disease of the lower limbs with the serotonergic antagonist naftidrofuryl: Results after 6 months of a controlled, multicenter study. Journal of Cardiovascular Pharmacology 1990;16(Suppl):75- 80.
3. Boccalon 2001 {published and unpublished data} Boccalon H, Lehert P, Mosnier M. Effect of naftidrofuryl on physiological walking distance in patients with intermittent claudication. Annales de Cardiologie et d Angeiologie 2001;50(3):175-82.
4. Kieffer 2001 {published and unpublished data} Kieffer E, Bahnini A, Mouren X, Gamand S. A new study demonstrates the efficacy of naftidrofuryl in the treatment of intermittent claudication International. Angiology 2001;20(1):58-65.
5. Kriessman 1988 {published and unpublished data} Kriessman A, Neiss A. Clinical effectiveness of naftidrofuryl in intermittent claudication [Naftidrofuryl bei der peripher arteriellen verschlusskrankheit]. VASA 1988;17(Suppl 24):27-32.
6. Maass 1984 {published and unpublished data} Maass U, Amberger H-G, Bohme H, Diehm C, Dimroth H, Heidrich H, et al.Naftidrofuryl in arterial occlusive disease [Naftidrofuryl bei arterieller Verschlusskrankheit. Kontrollierte multizentrische Doppelblindstudie mit oraler Applikation]. Deutsche Medizinische Wochenschrift 1984;109:745-50.
7. Moody 1994 {published and unpublished data} Moody AP, Al-Khaffaf HS, Lehert P, Harris PL, Charlesworth D. An evaluation of patients with severe intermittent claudication and the effect of treatment with naftidrofuryl. Journal of Cardiovascular Pharmacology 1994;23(Suppl 3):44-7.
8. Clyne 1980 Clyne CAC, Galland RB, Fox MJ, Gustave R, Jantet GH, Jamieson CW. A controlled trial of naftidrofuryl (Praxilene) in the treatment of intermittent claudication. British Journal of Surgery 1980;67:347-8.
9. Karnik 1988 Karnik R, Valentin A, Stollberger C, Slany J. Effects of naftidrofuryl in patients with intermittent claudication. Angiology 1988;39 (3):234-40.
10. Pohle 1979 Pohle W, Hirche H, Barmeyer J, Schumichen C, Hoffman G. A double-blind trial of naftidrofuryl hydrogen oxalate in patients suffering from occlusive peripheral arterial disease. Medizinische Welt 1979;30 (7):269-72.
11. Ruckley 1978 Ruckley CV, Callam MJ, Ferrington CM, Prescott RJ. Naftidrofuryl for intermittent claudication: a double-blind controlled trial. British Medical Journal 1978;1:622.
12. Anderson 1957 Anderson TW. Maximum likelihood estimates for amultivariate normal distribution when some observations are missing. Journal of the American Statistical Association 1957;52:200-3.
13. Aung 2007 Aung PP, Maxwell HG, Jepson RG, Price JF, Leng GC. Lipid-lowering for peripheral arterial disease of the lower limb. Cochrane Database of Systematic Reviews 2007, Issue 4.Art. No.: CD000123. DOI:10.1002/14651858.CD000123.pub2.
14. Burns 2003 Burns P, Gough S, Bradbury AW. Management of peripheral arterial disease in primary care. BMJ 2003;326(7389):584-8.
15. Cameron 1988 Cameron HA, Waller PC, Ramsay LE. Drug treatment of intermittent claudication: a critical analysis of the methods and findings of published clinical trials, 1965-1985. British Journal of Clinical Pharmacology 1988;26(5):569-76.
16. Carman 2000 Carman TL, Fernandez BB Jr. A primary care approach to the patient with claudication. American Family Physician 2000;61(4):1027-32, 1034.
17. CLIPS 2007 Critical Leg Ischaemia Prevention Study (CLIPS) Group, Catalano M, Born G, Peto R. Prevention of serious vascular events by aspirin amongst patients with peripheral arterial disease: randomized, double-blind trial. Journal of Internal Medicine 2007;261(3):276-84.
18. Coffman 1979 Coffman JD. Intermittent claudication and rest pain: physiologic concepts and therapeutic approaches. Progress in Cardiovascular Diseases 1979;22(1):53-72.
19. Cohen 1988 Cohen J. Statistical power analysis for the behavioral sciences. 2nd Edition. New Jersey: Lawrence Erlbaum, 1988.
20. CPMP Working Party CPMP Working Party. Clinical investigations of medicinal products in the treatment of chronic peripheral arterial disease. Note for guidance EMEA Status as of October 2002. http://www.emea.europa.eu/pdfs/ human/ewp/071498en.pdf (accessed 23 May 2007).
21. Criqui 1985 Criqui MH, Fronek A, Barrett-Connor E, Klauber MR, Gabriel S, Goodman D. The prevalence of peripheral arterial disease in a defined population. Circulation 1985;71(3):510-5.
22. D'Hooge 2001 D'Hooge D, Lehert P, Clement DL. Naftidrofuryl in quality of life (NIQOL). A Belgian Study. International Angiology 2001;20(4):288-94.
23. De Backer 2000 De Backer TL, Vander Stichele RH, Bogaert MG. Buflomedil for intermittent claudication. Cochrane Database of Systematic Reviews 2007, Issue 4.Art. No.: CD000988. DOI: 10.1002/14651858.CD000988. pub3.
24. De Backer 2000b De Backer TL, Vander Stichele RH, Warie HH, Bogaert MG. Oral vasoactive medication in intermittent claudication: utile or futile?. European Journal of Clinical Pharmacology 2000;56(3):199- 206.
25. DerSimonian 1986 DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials 1986;7(3):177-88.
26. Diehm 2004 Diehm C, Schuster A, Allenberg JR, Darius H, Haberl R, Lange S, et al.High prevalence of peripheral arterial disease and co-morbidity in 6880 primary care patients: cross-sectional study. Atherosclerosis 2004;172(1):95-105.
27. Dormandy 2000 Dormandy JA, Rutherford RB. Management of peripheral arterial disease (PAD). TASC Working Group. Trans Altlantic Inter-Society Consensus (TASC). Journal of Vascular Surgery 2000;31(Pt 2):1-296.
28. Egger 1997 Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315(7109): 629-34.
29. EMEA The European Agency for the Evaluation of Medicinal Products (EMEA). ICHTopic E 6. Guideline for Good Clinical Practice. http: //www.emea.eu.int/pdfs/human/ich/013595en.pdf (accessed 28 August 2004).
30. Fontaine 1954 Fontaine VR, Kim M, Kieny R. Surgical treatment for peripheral vascular disease [Die chirurgische Behandlung der peripheren Durchblutungsstorungen]. Helvetica Chirurgica Acta 1954;21:499- 533.
31. Fowkes 1991 Fowkes FG, Housley E, Cawood EH, MacIntyre CA, Ruckley CV, Prescott RJ. Edinburgh artery study: prevalence of asymptomatic and symptomatic peripheral arterial disease in the general population. International Journal of Epidemiology 1991;20(2):384-92.
32. Gehr 2006 Gehr BT, Weiss C, Porzsolt F. The fading of reported effectiveness. A meta-analysis of randomized controlled trials. BMC Medical Research Methodology 2006;6(25):1-12.
33. Girolami 1999 Girolami B, Bernardi E, Prins MH, Ten Cate JW, Hettiarachchi R, Prandoni P, et al.Treatment of intermittent claudication with physical training, smoking cessation, pentoxifylline, or nafronyl: a meta-analysis. Archives of Internal Medicine 1999;159(4):337-45.
34. Goldsmith 2005 Goldsmith DR, Wellington K. Naftidrofuryl: a review of its use in the treatment of intermittent claudication. Drugs & Aging 2005;22 (11):967-77.
35. Hiatt 1995 Hiatt WR, Hoag S, Hamman RF. Effect of diagnostic criteria on the prevalence of peripheral arterial disease. The San Luis Valley Diabetes Study. Circulation 1995;91(5):1472-9.
36. Higgins 2001 Higgins JP, Whitehead A, Turner RM, Omar RZ, Thompson SG. Meta-analysis of continuous outcome data from individual patients. Statistics in Medicine 2001;20:2219-41.
37. Hood 1996 Hood SC, Moher D, Barber GG. Management of intermittent claudication with pentoxifylline: meta-analysis of randomized controlled trials. Canadian Medical Association Journal 1996;155(8):1053-9.
38. Hooi 2004 Hooi JD, Kester AD, Stoffers HE, Rinkens PE, Knottnerus JA, van Ree JW. Asymptomatic peripheral arterial occlusive disease predicted cardiovascular morbidity and mortality in a 7-year follow-up study. Journal of Clinical Epidemiology 2004;57(3):294-300.
39. Jadad 1996 Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al.Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Controlled Clinical Trials 1996;17(1): 1-12.
40. Kleijnen 1998 Kleijnen J, Mackerras D. Vitamin E for intermittent claudication. Cochrane Database of Systematic Reviews 1998, Issue 1.Art. No.: CD000987. DOI:10.1002/14651858.CD000987.
41. Lehert 1990 Lehert P, Riphagen FE, Gamand S. The effect of naftidrofuryl on intermittent claudication: a meta-analysis. Journal of Cardiovascular Pharmacology 1990;16(Suppl 3):81-6.
42. Leng 2000 Leng GC, Fowler B, Ernst E. Exercise for intermittent claudication. Cochrane Database of Systematic Reviews 2000, Issue 1.Art. No.: CD000990. DOI:10.1002/14651858.CD000990.
43. Li 2003 Li XY, Wang J, He Y, Fan L. The relation between peripheral arterial occlusive disease and cardiovascular diseases in elderly population: a cross-section study in Wanshoulu area,Beijing. Chung-Hua i Hsueh Tsa Chih [Chinese Medical Journal] 2003;83(21):1847-51.
44. Mil-STD 105D Defense Standardization Program. Military Standards 105D - Quality on Data Entry process. http://www.dsp.dla.mil (accessed 27 August 2004).
45. Moher 2000 Moher D, Pham B, Ausejo M, Saenz A, Hood S, Barber GG. Pharmacological management of intermittent claudication: a meta-analysis of randomised trials. Drugs 2000;59(5):1057-70.
46. Mohler 2003 Mohler ER 3rd. Peripheral arterial disease: identification and implications. Archives of Internal Medicine 2003;163(19):2306-14.
47. Reiter 2003 Reiter M, Bucek RA, Stümpflen A, Minar E. Prostanoids for intermittent claudication. Cochrane Database of Systematic Reviews 2003, Issue 4.Art. No.: CD000986. DOI: 10.1002/14651858.CD000986. pub2.
48. Robless 2007 Robless P, Mikhailidis DP, Stansby GP. Cilostazol for peripheral arterial disease. Cochrane Database of Systematic Reviews 2007, Issue 2.Art. No.: CD003748. DOI:10.1002/14651858.CD003748.pub3.
49. SIGN 2006 Scottish Intercollegiate Guidelines Network. Diagnosis andmanagement of peripheral arterial disease. A national clinical guideline. Scottish Intercollegiate Guidelines Network (SIGN) 2006;89:1-41.
50. Sommerfield 2007 Sommerfield T, Price J, Hiatt WR. Omega-3 fatty acids for intermittent claudication. Cochrane Database of Systematic Reviews 2007, Issue 4.Art. No.: CD003833. DOI:10.1002/14651858.CD003833. pub3.
51. TASC II 2007 Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG, TASCII Working Group. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). European Journal of Vascular & Endovascular Surgery 2007;33 Suppl 1:1-75.
52. Turner 2000 Turner RM, Omar RZ, Yang M, Goldstein H, Thompson SG. A multilevel model framework for meta-analysis of clinical trials with binary outcomes. Statistics in Medicine 2000;19(24):3417-32.
53. Verhaege 1998 Verhaeghe R. Epidemiology and prognosis of peripheral obliterative arteriopathy. Drugs 1998;56(Suppl 3):1-10.
54. Walker 1995 Walker GA, Mac Hannaford JC. A meta-analysis of randomized, double-blind, placebo-controlled studies of the effect of buflomedil on intermittent claudication. Fundamental & Clinical Pharmacology 1995;9(4):387-94.
55. WHO World Health Organization. The Anatomical Therapeutic Chemical Classification System with Defined Daily Doses (ATC/DDD). http://www.who.int/ classifications/atcddd/en/ (accessed July 2007).
56. Ausejo 1999 Ausejo M, Saenz A, Hood S, Barber G, Pham B, Moher D. Naftidrofuryl for intermittent claudication (Protocol for a Cochrane Review). Cochrane Database of Systematic Reviews 1999, Issue 1.